The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene Therapeutics’ ALLO-329, an investigational allogenicCAR-T cell therapy. Researchers are preparing to a initiate the Phase 1 RESOLUTION trial in mid-2025 for people with autoimmune diseases, including systemic lupus erythematosus (SLE), lupus nephritis (LN), idiopathic inflammatory myopathies, and systemic sclerosis.
ALLO-329 is designed to target both CD19+ B cells and CD70+ activated T cells. The therapy utilizes CRISPR-based specific integration to enable dual CAR expression and incorporates Allogene’s clinically validated Dagger® technology. This technology is aimed at minimizing or eliminating the need for lymphodepletion, a pre-treatment regimen which can pose a significant barrier to CAR-T cell therapy.
Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about medications used to treat lupus.
This post was originally published on this site